Abstract
The past decade has seen a number of clinical vaccination trials investigating defined tumor antigens. These trials have taught us the immunologic consequences of various vaccination approaches, although the clinical efficacy of the vaccines has only reached the proof-of-concept level. Detailed and rigorous immune monitoring will be crucial for successful further development of cancer vaccines as well as defining patient populations likely to benefit. At a recent meeting of the Berlin Oncology Summer Seminar (BOSS) the clinical and translational cancer vaccine program ongoing at the Charité was presented, and this paper contains a summary of the presentation as well as the subsequent discussion.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Cilloni D, Saglio G (2004) WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Haematol 112:79–84
Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, Rosenberg SA, Marincola FM (1996) Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 3:37–44
Gaiger A, Carter L, Greinix H, Carter D, McNeill PD, Houghton RL, Cornellison CD, Vedvick TS, Skeiky YA, Cheever MA (2001) WT1-specific serum antibodies in patients with leukemia. Clin Cancer Res 7[3 Suppl]:761s–765s
Jaeger E, Ringhoffer M, Dienes HP, Arand M, Karbach J, Jaeger D, Ilsemann C, Hagedorn M, Oesch F, Knuth A (1996) GM-CSF enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 67:54–62
Keilholz U, Weber J, Finke JH, Gabrilovich DJ, Kast WM, Disis ML, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, Lyerly HK, Lee PP, Storkus W, Marincola F, Worobec A, Atkins MB (2002) Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 25:97–138
Lee P, Wang F, Kuniyoshi J, Rubio V, Stuges T, Groshen S, et al (2001) Effects of IL-12 on the immune response to a multipeptide vaccine for resected melanoma. J Clin Oncol 19:3836–3847
Mailaender V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, Keilholz U (2004) Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 18:165–166
Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Lienard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jager E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, Boon T (1999) Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80:219–230
Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, Elisseeva OA, Oji Y, Kawakami M, Ikegame K, Hosen N, Yoshihara S, Wu F, Fujiki F, Murakami M, Masuda T, Nishida S, Shirakata T, Nakatsuka S, Sasaki A, Udaka K, Dohy H, Aozasa K, Noguchi S, Kawase I, Sugiyama H (2004) Induction of WT1-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 101:13885–13890
Renkvist N, Castelli C, Robbins PF, Parmiani G (2001) A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50:3–15
Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE (1998) Immunologic and therapeutic evaluation of asynthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321–327
Rosenfeld C, Cheever MA, Gaiger A (2003) WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia 17:1301–1312
Scheibenbogen C, Schmittel A, Keilholz U, Allgäuer T, Hofmann U, Max R, Thiel E, Schadendorf D (2000) Phase II trial of vaccination with tyrosinase peptides and GM-CSF in melanoma. J Immunother 23:275–281
Scheibenbogen C, Nagorsen D, Seliger B, Schmittel A, Bauer S, Max N, Bock M, Atkins D, Thiel E, Keilholz U (2002a) Long-term freedom from recurrence in two high-risk melanoma patients following djuvant vaccination with tyrosinase peptides. Int J Cancer 99:403–408
Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S, Nagorsen D, Keilholz U (2002b) CD8 T cell responses to Wilms ‘tumor gene encoded protein WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 100:2132–2137
Scheibenbogen C, Schadendorf D, Bechrakis N, Nagorsen D, Hofmann U, Servetopoulou F, Letsch A, Philipp A, Foerster MH, Schmittel A, Thiel E, Keilholz U (2003) Effects of GM-CSF and foreign helper protein as immunological adjuvants on the T cell response to vaccination with tyrosinase peptides. Int J Cancer 104:188–194
Slingluff C, Yamshchikov GV, Neese P, Galavotti H, Eastham S, Engelhard V, et al (2001) Phase I trial of a melanoma vaccine with gp100 280–288 peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcome. Clin Cancer Res 7:3012–3024
Smith JW 2nd, Walker EB, Fox BA, Haley D, Wisner KP, Doran T, Fisher B, Justice L, Wood W, Vetto J, Maecker H, Dols A, Meijer S, Hu HM, Romero P, Alvord WG, Urba WJ (2003) Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol 21:1562–1573
Tsuboi A, Oka Y, Ogawa H, Elisseeva OA, Li H, Kawasaki K, Aozasa K, Kishimoto T, Udaka K, Sugiyama H (2000) Cytotoxic T-lymphocyte responses elicited to Wilms ‘tumor gene WT1 product by DNA vaccination. J Clin Immunol 20:195–202
van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643–1647
Van Dijk JP, Knops GH, Van De Locht LT, Menke AL, Jansen JH, Mensink EJ, Raymakers RA, De Witte T (2002) Abnormal WT1 expression in the CD34-negative compartment in myelodysplastic bone marrow. Br J Haematol 118:1027–1033
Weber J, Sondak VK, Scotland R, Phillip R, Wang F, Rubio V, Stuge TB, Groshen SG, Gee C, Jeffery GG, Sian S, Lee PP (2003) Granulocyte-macrophagecolony-stimulating factor added to a multipeptide vaccine for resected stage II melanoma. Cancer 97:186–200
Weber JS, Hua FL, Spears L, Marty V, Kuniyoshi C, Celis E (1999) A phase I trial of an HLA-A1-restricted MAGE-3 epitope peptide with IFA in patients with resected high-risk melanoma. J Immunother 5:431–440
Wu F, Oka Y, Tsuboi A, Elisseeva OA, Ogata K, Nakajima H, Fujiki F, Masuda T, Murakami M, Yoshihara S, Ikegame K, Hosen N, Kawakami M, Nakagawa M, Kubota T, Soma T, Yamagami T, Tsukaguchi M, Ogawa H, Oji Y, Hamaoka T, Kawase I, Sugiyama H (2005) Th-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies. Leukemia 19:268–274
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Keilholz, U. (2007). Antigen-Specific Cancer Vaccines. In: Dietel, M. (eds) Targeted Therapies in Cancer. Recent Results in Cancer Research, vol 176. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-46091-6_18
Download citation
DOI: https://doi.org/10.1007/978-3-540-46091-6_18
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-46090-9
Online ISBN: 978-3-540-46091-6
eBook Packages: MedicineMedicine (R0)